相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
Raymond Y. Huang et al.
CLINICAL CANCER RESEARCH (2016)
Contrast-Enhancing Tumor Growth Dynamics of Preoperative, Treatment-Naive Human Glioblastoma
Benjamin M. Ellingson et al.
CANCER (2016)
Patient and treatment factors associated with survival among adult glioblastoma patients: A USA population-based study from 2000-2010
I-Wen Pan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity
Mark E. Oppenlander et al.
JOURNAL OF NEUROSURGERY (2014)
Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma
Matthew M. Grabowski et al.
JOURNAL OF NEUROSURGERY (2014)
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
Kaisorn L. Chaichana et al.
NEURO-ONCOLOGY (2014)
Impact of imaging measurements on response assessment in glioblastoma clinical trials
David A. Reardon et al.
NEURO-ONCOLOGY (2014)
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2014)
Pros and cons of current brain tumor imaging
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2014)
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
Martha Nowosielski et al.
NEUROLOGY (2014)
Time window for postoperative reactive enhancement after resection of brain tumors: less than 72 hours
Stephanie Lescher et al.
NEUROSURGICAL FOCUS (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
Benjamin M. Ellingson et al.
RADIOLOGY (2014)
When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?
Kaisorn L. Chaichana et al.
WORLD NEUROSURGERY (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Probabilistic Radiographic Atlas of Glioblastoma Phenotypes
B. M. Ellingson et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
Jerrold L. Boxerman et al.
NEURO-ONCOLOGY (2013)
Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images
Kourosh M. Naeini et al.
NEURO-ONCOLOGY (2013)
Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma
J. A. Carrillo et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST plus F criteria
Jaime Gallego Perez-Larraya et al.
NEURO-ONCOLOGY (2012)
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
L. C. Hygino da Cruz et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
VALIDATION AND SIMPLIFICATION OF THE RADIATION THERAPY ONCOLOGY GROUP RECURSIVE PARTITIONING ANALYSIS CLASSIFICATION FOR GLIOBLASTOMA
Jing Li et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Radiographic patterns of relapse in glioblastoma
Marc C. Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2011)
An extent of resection threshold for newly diagnosed glioblastomas
Nader Sanai et al.
JOURNAL OF NEUROSURGERY (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004
Luc Bauchet et al.
NEURO-ONCOLOGY (2010)
Bidimensional Measurements in Brain Tumors: Assessment of Interobserver Variability
James M. Provenzale et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2009)
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Independent association of extent of resection with survival in patients with malignant brain astrocytoma
Matthew J. McGirt et al.
JOURNAL OF NEUROSURGERY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Glioma vascularity correlates with reduced patient survival and increased malignancy
Stephen M. Russell et al.
SURGICAL NEUROLOGY (2009)
Brain tumor imaging in clinical trials
J. W. Henson et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2008)
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
Felix Bokstein et al.
CANCER (2008)
Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
John F. de Groot et al.
CANCER JOURNAL (2008)
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
Tyler Y. Kang et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Time course of imaging changes of GBM during extended bevacizumab treatment
Suchitra Ananthnarayan et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Relationship between gene expression and enhancement in glioblastoma multiforme: Exploratory DNA microarray analysis
Whitney B. Pope et al.
RADIOLOGY (2008)
Response criteria for glioma
A. Gregory Sorensen et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Marc C. Chamberlain
NEUROLOGY (2006)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
MD Prados et al.
NEURO-ONCOLOGY (2006)
Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods
E Galanis et al.
NEURO-ONCOLOGY (2006)
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas
GD Shah et al.
NEURO-ONCOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project
ER Laws et al.
JOURNAL OF NEUROSURGERY (2003)
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen
TF Cloughesy et al.
CANCER (2003)
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma
E Raymond et al.
ANNALS OF ONCOLOGY (2003)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
M Lacroix et al.
JOURNAL OF NEUROSURGERY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
